# Concurrent Induction Chemoimmunotherapy With Epirubicine, Oxaliplatin, Capecitabine and Panitumumab in KRAs Wild-type, Resectable Type II Gastric Adenocarcinoma

> **NCT01351038** · PHASE2 · TERMINATED · sponsor: **Arbeitsgemeinschaft medikamentoese Tumortherapie** · enrollment: 43 (estimated)

## Conditions studied

- KRAS Wild Type
- Resectable Type II Gastric Adenocarcinoma

## Interventions

- **DRUG:** Epirubicine, Oxaliplatin, Capecitabine, Panitumumab

## Key facts

- **NCT ID:** NCT01351038
- **Lead sponsor:** Arbeitsgemeinschaft medikamentoese Tumortherapie
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** —
- **Primary completion:** —
- **Final completion:** —
- **Target enrollment:** 43 (ESTIMATED)
- **Why stopped:** REAL trial showed a significant difference in OS for reduced EOX and standard EOX
- **Last updated:** 2013-06-04

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01351038

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01351038, "Concurrent Induction Chemoimmunotherapy With Epirubicine, Oxaliplatin, Capecitabine and Panitumumab in KRAs Wild-type, Resectable Type II Gastric Adenocarcinoma". Retrieved via AI Analytics 2026-07-25 from https://api.ai-analytics.org/clinical/NCT01351038. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*